Promoter holding
64.27%
RL
Ripharma Laboratories Limited - Due diligence report
A 360° intelligence report on Ripharma Laboratories Limited: trust score, financial health, credit view, compliance, directors, growth and d…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Ripharma Laboratories Limited — 360° Intelligence Report
Generated from MCA filings & public records86/100
Trust Score
Low Risk
Ripharma Laboratories Limited is assessed as Low Risk with a Trust Score of 86/100. Ripharma Laboratories Limited is an active public limited indian non-government company incorporated in 2015, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 16 Aug 2026 from the latest processed filings. Ripharma Laboratories Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
86/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 2 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Profitable - internal accruals available.
Charges position: 1 open (4.90 cr) · 0 satisfied (-).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 1 | 48.0 cr |
Compliance Score: 93/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 45/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RISHABH SHREEPAL JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHANTILAL RAJMAL JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHREEPAL CHAMPALAL JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHRENIK CHAMPALAL JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MILAN CHAMPALAL JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AMIT SHANTILAL JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 6 directors on the board.
- SHANTILAL RAJMAL JAIN has DIN status "Disqualified by RoC u/s 164(2)".
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2025)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 1 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
Net margin improved to 38%.
Operating for 11+ years.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence90/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment92/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 4.90 cr already registered.
- Compliance record supports lending.
Investor view93/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 12 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
04 Feb 2025
Director appointed
SHANTILAL RAJMAL JAIN (Director)
23 Jan 2025
Charge created
Others - 4.90 cr
13 Feb 2024
Director ceased
CHAMPALAL RAJMAL JAIN
16 Sep 2018
Director ceased
SHANTILAL RAJMAL JAIN
25 Mar 2015
Incorporated
Registered with Roc Mumbai
Director appointed
RISHABH SHREEPAL JAIN (Director)
Director appointed
SHREEPAL CHAMPALAL JAIN (Director)
Director appointed
SHRENIK CHAMPALAL JAIN (Director)
Director appointed
MILAN CHAMPALAL JAIN (Director)
Director appointed
AMIT SHANTILAL JAIN (Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 1.42 over the last 1 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
6 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Newjaisa | L32106KA2020PLC134935 | Bangalore South, Karnataka, India |
| Aadhar Infraprojects Private Limited | U45201RJ2010PTC032400 | Jaipur, Rajasthan, India |
| Gstc.Com | U33119DL2012PLC235348 | New Delhi, Delhi, India |
| Kamanwala Housing Construction Limited | L65990MH1984PLC032655 | Mumbai, Maharashtra, India |
| Panicle Foods Private Limited | U15142DL2016PTC289756 | New Delhi, Delhi, India |
| Doit Industries Limited | U29253MH2010PLC209289 | Mumbai, Maharashtra, India |
| Akg-Global | L00063HR2005PLC119497 | Gurgaon, Haryana, India |
| Parmeshwar Impex Private Limited | U51900GJ2009PTC057563 | Surat, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Ripharma Laboratories Limited before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Ripharma Laboratories Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Ripharma Laboratories Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 86/100, distress signals and MSME payment-delay disclosures - know whether Ripharma Laboratories Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Ripharma Laboratories Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Ripharma Laboratories Limited an active company?
Ripharma Laboratories Limited has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is Ripharma Laboratories Limited financially healthy?
Ripharma Laboratories Limited has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Ripharma Laboratories Limited?
Its overall Trust Score is 86/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Ripharma Laboratories Limited?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 6 active director(s) are on record.
Does Ripharma Laboratories Limited have loans or charges against its assets?
1 open charge(s) are registered against its assets.
Is Ripharma Laboratories Limited up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to Ripharma Laboratories Limited?
Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
